ClinicalTrials.gg
RecruitingNCT06469788TANGOUpdated Oct 22, 2026

Testimonials and Navigation in Rheumatology

An interventional study of Video comprised of AIRD patient narratives on COVID-19 vaccination thoughts and experiences and Video on the importance of good oral health for patients with AIRD in Rheumatologic Disease and Autoimmune Diseases, sponsored by University of Alabama at Birmingham. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Oct 22, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 341 studies in Autoimmune Diseases with a site in United States — 91 open to participants now, 117 under way, 19 of them phase 3. Autoimmune Diseases · United States.

Planned enrollment
9th of 243
1,170 · median 53
Started
2024
with 22 others
No phase
29 of 341
7 open now
Primary completion
2027-09
later than 39 of 111 live
Registered
296th of 341
by date

Among the 341 studies in Autoimmune Diseases with a site in United States, this one is the 9th largest by planned enrollment of the 243 interventional ones that give a count, is one of 23 that started in 2024, is one of 29 with no phase, reaches primary completion later than 39 of the 111 other live ones, and was the 296th registered.

Autoimmune Diseases

804 studies on the registry are indexed under Autoimmune Diseases; 273 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

91 of the 341 studies in Autoimmune Diseases with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 341 studies in Autoimmune Diseases with a site in United States, or all of them as a file.
02

Study summary

The overall goal of this study is to determine whether a novel, multi-modal, patient-directed behavioral intervention initiated in rheumatology clinics is an effective approach to improve uptake of updated COVID-19 vaccine.

Read the detailed description

Black and Latinx persons are at higher risk for certain autoimmune and inflammatory rheumatic diseases (AIRD) and have experienced worse COVID-19 outcomes compared to their white counterparts. Given the risks of severe COVID-19 outcomes such as hospitalization and death in people with AIRD, COVID-19 vaccine is recommended in this population. Historically, overall vaccine uptake among people with AIRDs has been low, and this vaccine reluctance has extended to COVID-19 vaccination. While additional COVID-19 vaccine doses have offered considerable added protection against severe outcomes, only 20% of all vaccinated persons in Alabama (AL) and 45% in Massachusetts have obtained an additional dose of COVID-19 vaccine as of October 2022. Racial and ethnic minority groups have faced disparities in obtaining subsequent COVID-19 vaccines, particularly in under-resourced communities, including those in Alabama, Massachusetts, and Illinois. Together, these obstacles exacerbate existing health inequities among people of color and perpetuate worse COVID-19 outcomes.

We will conduct a randomized controlled study to test an intervention that seeks to address gaps in COVID-19 vaccine information and access inequities common in Black and Latinx populations.

03

Conditions studied

  • Rheumatologic Disease
  • Autoimmune Diseases

Keywords

  • COVID-19 vaccination
  • Rheumatic Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (18+ years) with known AIRD
  • Black race and/or Latinx ethnicity
  • Individuals who have not obtained the updated COVID-19 vaccine series (self-report)

Exclusion criteria

Exclusion Criteria:

-Lack of access to phone

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Investigator)
Enrollment
1,170 participants (estimated)

Study arms

  • Experimental
    "Storytelling" video including patient narratives, brochure and patient navigation

    Participants will review video with narratives on COVID-19 vaccination in patients with AIRD, receive brochure on the same topic; and interact with patient navigators.

    Behavioral: Video comprised of AIRD patient narratives on COVID-19 vaccination thoughts and experiences · Behavioral: Brochure on COVID-19 vaccination in AIRD patients · Behavioral: Patient Navigation

  • Active comparator
    Attention Control: "Oral Health" video and "Oral Health" brochure

    Participants will review video on the importance of oral health in patients with AIRD and receive brochure on the same topic.

    Behavioral: Video on the importance of good oral health for patients with AIRD · Behavioral: Brochure on the importance of good oral health in AIRD patients

Interventions

  • BehavioralVideo comprised of AIRD patient narratives on COVID-19 vaccination thoughts and experiences

    Participants will watch video focused on the importance of receipt of updated COVID-19 vaccination in patients with AIRD

  • BehavioralVideo on the importance of good oral health for patients with AIRD

    Participants will watch video on the importance of good oral health in AIRD patients.

    Also known as: Attention Control

  • BehavioralBrochure on COVID-19 vaccination in AIRD patients

    Participants

  • BehavioralPatient Navigation

    Participants will receive phone calls from patient navigators to provide support and information for receipt of updated COVID-19 vaccination in patients with AIRD

  • BehavioralBrochure on the importance of good oral health in AIRD patients

    Participants will receive a brochure on the importance of good oral health in AIRD patients.

06

What researchers measure

Primary outcomes

  1. Receipt of updated COVID-19 vaccination.

    We will measure rates of receipt of updated COVID-19 vaccination.

    Time frame: 3 months

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Feldman CH, Ramsey-Goldman R. Widening Disparities Among Patients With Rheumatic Diseases in the COVID-19 Era: An Urgent Call to Action. Arthritis Rheumatol. 2020 Sep;72(9):1409-1411. doi: 10.1002/art.41306. Epub 2020 Aug 9. No abstract available. PubMed 32379381 ↗
  • Hmamouchi I, Winthrop K, Launay O, Dougados M. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine. 2015 Mar 17;33(12):1446-52. doi: 10.1016/j.vaccine.2015.01.065. Epub 2015 Feb 7. PubMed 25659279 ↗
  • Costello R, Winthrop KL, Pye SR, Brown B, Dixon WG. Influenza and Pneumococcal Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Immunosuppressive Therapy in the UK: A Retrospective Cohort Study Using Data from the Clinical Practice Research Datalink. PLoS One. 2016 Apr 20;11(4):e0153848. doi: 10.1371/journal.pone.0153848. eCollection 2016. PubMed 27096429 ↗
  • Boucher VG, Pelaez S, Gemme C, Labbe S, Lavoie KL. Understanding factors associated with vaccine uptake and vaccine hesitancy in patients with rheumatoid arthritis: a scoping literature review. Clin Rheumatol. 2021 Feb;40(2):477-489. doi: 10.1007/s10067-020-05059-7. Epub 2020 Jul 3. PubMed 32621081 ↗
  • Hua C, Morel J, Ardouin E, Ricard E, Foret J, Mathieu S, Combe B, Lukas C. Reasons for non-vaccination in French rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2015 Apr;54(4):748-50. doi: 10.1093/rheumatology/keu531. Epub 2015 Feb 8. No abstract available. PubMed 25667433 ↗
  • Qendro T, de la Torre ML, Panopalis P, Hazel E, Ward BJ, Colmegna I, Hudson M. Suboptimal Immunization Coverage among Canadian Rheumatology Patients in Routine Clinical Care. J Rheumatol. 2020 May 1;47(5):770-778. doi: 10.3899/jrheum.181376. Epub 2019 Jul 15. PubMed 31308211 ↗
  • Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, Calabrese C, Gravallese EM, Harpaz R, Kroger A, Sadun RE, Turner AS, Williams EA, Mikuls TR. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. Arthritis Rheumatol. 2021 Oct;73(10):e60-e75. doi: 10.1002/art.41928. Epub 2021 Aug 4. PubMed 34346564 ↗
  • Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R, Scher JU, Guttmann A, Carlucci PM, Deonaraine KK, Golpanian M, Robins K, Chang M, Belmont HM, Buyon JP, Blazer AD, Saxena A, Izmirly PM; NYU WARCOV Investigators. Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 Dec;72(12):1971-1980. doi: 10.1002/art.41450. Epub 2020 Oct 28. PubMed 32715660 ↗
  • Gianfrancesco MA, Leykina LA, Izadi Z, Taylor T, Sparks JA, Harrison C, Trupin L, Rush S, Schmajuk G, Katz P, Jacobsohn L, Hsu TY, D'Silva KM, Serling-Boyd N, Wallwork R, Todd DJ, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Wallace ZS, Machado PM, Robinson PC, Yazdany J; COVID-19 Global Rheumatology Alliance. Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol. 2021 Mar;73(3):374-380. doi: 10.1002/art.41567. Epub 2021 Feb 2. PubMed 33146001 ↗
  • Taylor T, Yazdany J, Gianfrancesco MA. The racial/ethnic and sociocultural aspects of the pandemic in rheumatology. Best Pract Res Clin Rheumatol. 2021 Mar;35(1):101665. doi: 10.1016/j.berh.2021.101665. Epub 2021 Feb 18. PubMed 33648855 ↗
  • Raiker R, DeYoung C, Pakhchanian H, Ahmed S, Kavadichanda C, Gupta L, Kardes S. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States. Semin Arthritis Rheum. 2021 Oct;51(5):1057-1066. doi: 10.1016/j.semarthrit.2021.08.010. Epub 2021 Aug 20. PubMed 34450504 ↗
  • Pablos JL, Galindo M, Carmona L, Lledo A, Retuerto M, Blanco R, Gonzalez-Gay MA, Martinez-Lopez D, Castrejon I, Alvaro-Gracia JM, Fernandez Fernandez D, Mera-Varela A, Manrique-Arija S, Mena Vazquez N, Fernandez-Nebro A; RIER Investigators Group; RIER investigators group. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis. 2020 Dec;79(12):1544-1549. doi: 10.1136/annrheumdis-2020-218296. Epub 2020 Aug 12. PubMed 32796045 ↗
  • England BR, Roul P, Yang Y, Kalil AC, Michaud K, Thiele GM, Sauer BC, Baker JF, Mikuls TR. Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals. Arthritis Rheumatol. 2021 Dec;73(12):2179-2188. doi: 10.1002/art.41800. Epub 2021 Oct 19. PubMed 33955209 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Sep 2027, 32 months after the start.

Of 78 non-industry interventional studies with no phase under Autoimmune Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 62. This study's planned 32 months is close to that.

Counting every sponsor, half of 87 studies reached it within 31 months; a quarter within 15 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2024
First posted
Jun 24, 2024
StartActual
Dec 18, 2024
Primary completionEst.
Sep 15, 2027
CompletionEst.
May 31, 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Brigham Women's Hospital · Boston, United StatesNot yet recruiting→Recruiting
  • University of Massachusetts Chan Medical School · Worcester, United StatesNot yet recruiting→Recruiting
Show site
  • Northwestern University · Evanston, United States
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    1 site added. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Brigham Women's Hospital · Boston, United StatesNot yet recruiting→Recruiting
    • University of Massachusetts Chan Medical School · Worcester, United StatesNot yet recruiting→Recruiting
    Show site
    • Northwestern University · Evanston, United States
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06469788
Responsible party
Maria Danila, MD, MSc, MSPH (Professor of Medicine, University of Alabama at Birmingham) — Principal investigator
First posted
Jun 24, 2024
Start date
Dec 18, 2024
Primary completion
Sep 15, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Mary A Wilkenson, Clinical Research Coordinator, BS
Contact
mawilkenson@uabmc.edu
205-996-7875
Paolo Rusconi, Project Director, PhD
Contact
paolorusconi@uabmc.edu
Maria I Danila, MD, MSc, MSPH
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion